652 Eli Lilly and Company $LLY Shares Sold by Joel Isaacson & Co. LLC

Joel Isaacson & Co. LLC reduced its holdings in Eli Lilly and Company (NYSE:LLY) by 5.6% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,046 shares of the company’s stock after selling 652 shares during the quarter. Joel Isaacson & Co. LLC’s holdings in Eli Lilly and Company were worth $12,781,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of LLY. Torren Management LLC raised its position in Eli Lilly and Company by 357.1% in the third quarter. Torren Management LLC now owns 32 shares of the company’s stock worth $37,000 after acquiring an additional 25 shares in the last quarter. Marshall & Sterling Wealth Advisors Inc. lifted its holdings in Eli Lilly and Company by 60.0% in the first quarter. Marshall & Sterling Wealth Advisors Inc. now owns 40 shares of the company’s stock valued at $37,000 after acquiring an additional 15 shares during the period. Foresight Capital Management Advisors Inc. purchased a new stake in shares of Eli Lilly and Company during the 3rd quarter worth $49,000. AlphaCentric Advisors LLC purchased a new stake in shares of Eli Lilly and Company during the 1st quarter worth $42,000. Finally, Caitlin John LLC purchased a new stake in shares of Eli Lilly and Company during the 2nd quarter worth $64,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $1,437.46 on Thursday. The stock has a fifty day moving average price of $1,231.13 and a 200 day moving average price of $1,106.42. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.00 and a current ratio of 1.39. The stock has a market cap of $1.35 trillion, a PE ratio of 46.66, a P/E/G ratio of 1.72 and a beta of 0.40. Eli Lilly and Company has a 1 year low of $850.51 and a 1 year high of $1,453.00.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, October 29th. The company reported $7.48 earnings per share for the quarter, beating the consensus estimate of $5.71 by $1.77. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. The company had revenue of $24.40 billion for the quarter, compared to analyst estimates of $22.58 billion. During the same quarter in the prior year, the company earned $7.02 earnings per share. Eli Lilly and Company’s revenue was up 38.6% compared to the same quarter last year. Sell-side analysts forecast that Eli Lilly and Company will post 35.67 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be given a $1.73 dividend. The ex-dividend date is Friday, November 13th. This represents a $6.92 annualized dividend and a dividend yield of 0.5%. Eli Lilly and Company’s payout ratio is currently 22.46%.

Trending Headlines about Eli Lilly and Company

These are some of the LLY headlines that stood out recently:

• Positive Sentiment: Lilly reported positive 52-week Phase 3b results for Taltz plus Zepbound in adults with psoriatic arthritis and obesity. Nearly three times as many combination-treatment patients achieved at least a 50% reduction in disease activity versus Taltz alone, potentially broadening Zepbound’s use and commercial opportunity. Article: Phase 3b Taltz and Zepbound results
• Negative Sentiment: The FDA is requiring GLP-1 drugmakers to add a warning about rare NAION-related vision loss. Zepbound is among the medicines affected, creating a potential safety concern for Lilly’s key product category. Article: FDA warning on GLP-1 drugs
• Negative Sentiment: Possible new U.S. drug-price negotiations could put pressure on Lilly revenue, according to a report identifying the company as facing nearer-term pricing exposure. Article: Drug-pricing risks

Insider Transactions at Eli Lilly and Company

In related news, EVP Anat Hakim sold 5,000 shares of the stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total value of $7,012,600.00. Following the sale, the executive vice president directly owned 4,137 shares of the company’s stock, valued at approximately $5,802,225.24. This represents a 54.72% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the firm’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the transaction, the executive vice president owned 54,147 shares of the company’s stock, valued at $63,628,139.70. This trade represents a 10.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.14% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the stock. The Goldman Sachs Group reaffirmed a “buy” rating and set a $1,413.00 price target on shares of Eli Lilly and Company in a research note on Tuesday, October 20th. Royal Bank Of Canada raised their price objective on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the company an “outperform” rating in a research note on Friday, October 30th. TD Cowen reissued a “buy” rating and set a $1,250.00 price objective on shares of Eli Lilly and Company in a report on Tuesday, September 22nd. UBS Group boosted their price objective on shares of Eli Lilly and Company from $1,425.00 to $1,625.00 and gave the stock a “buy” rating in a report on Friday, October 30th. Finally, Argus upped their target price on shares of Eli Lilly and Company from $1,300.00 to $1,550.00 and gave the stock a “buy” rating in a research report on Friday, October 30th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $1,416.64.

Eli Lilly and Company Company Profile

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.